aStem-M-POF
Pre-clinical- Indications
- Premature ovarian failure
Company intelligence / Profile preview
Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. develops regenerative therapies based on human umbilical cord-derived mesenchymal stem cells. Their preclinical and early clinical studies have shown promising safety and efficacy in immune-mediated diseases such as ankylosing spondylitis, psoriasis, ischemic stroke, and liver cirrhosis. Clinical results indicate significant improvements in disease activity indices for ankylosing spondylitis with good tolerability profiles. The company’s technology leverages the immunomodulatory and regenerative properties of hUCMSCs prepared under GMP conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Asia Stem Cell Regenerative Pharmaceutical Co., Ltd..